Who
Chris A. Rallis
Director
Company insider
Files Form 4 as: Director, Fennec Pharmaceuticals; Director, Tenax Therapeutics; Director, Aeolus Pharmaceuticals.
In numbers
- Trades disclosed
- 113
- Buys
- 0
- Sells
- 17
- Bought
- $0
- Sold
- $356K
- Companies
- 3
- Companies where not an officer
- 3
- First trade
- 12 Sep 2006
- Last trade
- 10 Jun 2026
- Last filed
- 10 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 10 Jun 2026filed 10 Jun 2026 | FENC Fennec Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | $174K20,000 at $8.70 | filing |
| 10 Jun 2026filed 10 Jun 2026 | FENC Fennec Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | $174K20,000 at $8.70 | filing |
| 11 May 2026filed 12 May 2026 | FENC Fennec PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $35K14,344 at $2.44 | filing |
| 11 May 2026filed 12 May 2026 | FENC Fennec PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $59K8,346 at $7.04 | filing |
| 11 May 2026filed 12 May 2026 | FENC Fennec Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | $35K14,344 at $2.44 | filing |
| 11 May 2026filed 12 May 2026 | FENC Fennec Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | $35K14,344 at $2.44 | filing |
| 11 May 2026filed 12 May 2026 | FENC Fennec PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $35K14,344 at $2.44 | filing |
| 11 May 2026filed 12 May 2026 | FENC Fennec PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $59K8,346 at $7.04 | filing |
| 10 Oct 2025filed 14 Oct 2025 | FENC Fennec Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | $4,9964,062 at $1.23 | filing |
| 10 Oct 2025filed 14 Oct 2025 | FENC Fennec PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $4,9964,062 at $1.23 | filing |
| 10 Oct 2025filed 14 Oct 2025 | FENC Fennec PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $16K1,775 at $9.24 | filing |
| 7 Jul 2025filed 7 Jul 2025 | FENC Fennec Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | $4,9982,127 at $2.35 | filing |
| 7 Jul 2025filed 7 Jul 2025 | FENC Fennec PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $4,9982,127 at $2.35 | filing |
| 7 Jul 2025filed 7 Jul 2025 | FENC Fennec PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $9,7461,119 at $8.71 | filing |
| 3 Jun 2025filed 4 Jun 2025 | FENC Fennec Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | $158K20,000 at $7.88 | filing |
| 11 Apr 2025filed 11 Apr 2025 | FENC Fennec Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | $4,9982,173 at $2.30 | filing |
| 11 Apr 2025filed 11 Apr 2025 | FENC Fennec PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $4,9982,173 at $2.30 | filing |
| 11 Apr 2025filed 11 Apr 2025 | FENC Fennec PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $6,9751,409 at $4.95 | filing |
| 14 Feb 2025filed 14 Feb 2025 | FENC Fennec Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | $5,0001,992 at $2.51 | filing |
| 14 Feb 2025filed 14 Feb 2025 | FENC Fennec PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $5,0001,992 at $2.51 | filing |
News
No headline names them, or the companies they trade most, lately.